Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6
- PMID: 17187414
- DOI: 10.1002/hep.21505
Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6
Comment on
-
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.Hepatology. 2006 May;43(5):954-60. doi: 10.1002/hep.21159. Hepatology. 2006. PMID: 16628671
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical